Skip to content
  • KOSPI 2733.18 -19.82 -0.72%
  • KOSDAQ 859.32 -11.05 -1.27%
  • KOSPI200 371.54 -3.06 -0.82%
  • USD/KRW 1355.3 +4.3 +0.32%
  • JPY100/KRW 869.59 +0.25 +0.03%
  • EUR/KRW 1471.72 +3.59 +0.24%
  • CNH/KRW 187.47 +0.42 +0.22%
View Market Snapshot
Bio & Pharma

NGeneBio to transfer NGS tech to UAE company

It will hand over the techs of diagnostic medical devices to Dubai-based Euro Alliance, with royalties for 10 years

By Apr 30, 2024 (Gmt+09:00)

1 Min read

NGeneBio　to　transfer　NGS　tech　to　UAE　company　

South Korean medical diagnostic company NGeneBio Co. announced on Tuesday that it signed a contract with the United Arab Emirates (UAE)-based medical company Euro Alliance to transfer next-generation sequencing (NGS)-based precision diagnostic medical device manufacturing technology.

Euro Alliance is an investment and medical technology commercialization specialist company based in Switzerland and Dubai, the UAE. It conducts healthcare-related businesses in India as well.

Under the contract, NGeneBio will transfer NGS precision diagnostic products, analysis software, and production know-how to Euro Alliance in the UAE region.

The two companies will also establish a joint venture in India and the UAE for NGS business operations.

NGeneBio will receive royalties proportional to future sales over the 10 years as fees for the technology transfer. Meanwhile, Euro Alliance will handle business operations and infrastructure investments.

Write to Jeong Min Nam at peux@hankyung.com
#NGeneBio #Euro Alliance #next-generation sequencing #NGS #precision diagnostic medical device #UAE
More to Read
Comment 0
0/300